Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q3 2020 · 10-Q
Revenue$0.00$0.00— vs Q3 2019 Net Income-$73.10K-$73.10KN/M vs Q3 2019 EPS Diluted$0.00$0.00— vs Q3 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
-$71,541
N/M
Operating Cash Flowderived-$64,601N/M ended Sep 30, 2020 · filed Nov 17, 2020 · 48 d after period end